MedTrace Logo

Treatment Efficacy and Safety of TDF-TAF Switch Study in South Korea

NCT03559790 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2019-01-30

No results posted yet for this study

Summary

Recent TAF has introduced to have more safe profiles than TDF in clinical trials. Especially, TDF has the renal safety issue in high risk group including HIV, decompensated cirrhosis (ascites), uncontrolled DM etc.

However, there is no available cohort data for treatment efficacy and safety in TDF-TAF switch therapy in treatment-naïve chronic hepatitis B.

The aim of this study is to evaluate safety and efficacy of TAF switch therapy in patients with chronic hepatitis B who have been treated with TDF.

Conditions

Interventions

DRUG

tenofovir alafenamide

To evaluate of efficacy and safety in patients with TDF-TAF switch therapy

Sponsors & Collaborators

  • The Catholic University of Korea

    lead OTHER

Principal Investigators

  • Myeong Jun Song · Daejeon St. Mary's hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-18
Primary Completion
2020-08-31
Completion
2021-08-31
FDA Drug
Yes

Countries

  • South Korea

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03559790 on ClinicalTrials.gov